On Feb. 21, PDL BioPharma
- Revenues rose 29%, backed by a 31% growth in royalties and a 23% growth in sales of products.
- Net loss has widened, primarily due to asset impairment charges to the tune of $72.1 million related to the company's Retavase product.
- Cash flow generated from operating activities for fiscal 2006 was $78.8 million, compared with $31.6 million for the full year 2005.
- The company anticipates total revenues for fiscal 2007 to be around $450 million-$500 million and non-GAAP EPS of $0.38 to $0.54.
- PDL Biopharma is highly regarded in Motley Fool CAPS, sporting a four-star rating.
(Figures in thousands, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$107,842 |
$83,653 |
28.9% |
|
Net Profit |
($89,708) |
($34,096) |
N/A |
|
EPS |
($0.78) |
($0.31) |
N/A |
|
Diluted Shares |
114,403 |
111,571 |
2.5% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
77.4% |
80.0% |
(2.6) |
|
Operating Margin |
(84.4%) |
(42.0%) |
(42.4) |
|
Net Margin |
(83.2%) |
(40.8%) |
(42.4) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$426,285 |
$333,922 |
27.7% |
|
Accounts Rec. |
No Data |
No Data |
No Data |
|
Inventory |
No Data |
No Data |
No Data |
Data for liabilities not available.
Learn the ways of the balance sheet.
Cash Flow Highlights
|
2006 |
2005 |
Change |
|
|---|---|---|---|
|
Cash From Ops. |
$78,770 |
$31,550 |
149.7% |
|
Capital Expenditures |
No Data |
No Data |
N/A |
|
Free Cash Flow |
No Data |
No Data |
N/A |
Find out why Fools always follow the money.
Related Companies:
-
Genentech
(NYSE:DNA) -
Medicines Co.
(NASDAQ:MDCO) -
Medarex
(NASDAQ:MEDX) -
Elan
(NYSE:ELN) -
Millennium Pharmaceuticals
(NASDAQ:MLNM)
Related Foolishness:
PDL Biopharma and Millennium Pharmaceuticals are Rule Breakers recommendations. Keep tabs on big events in tiny technology with a free 30-day trial subscription to David Gardner's Motley Fool Rule Breakers.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
